InVivoMAb anti-mouse FasL (CD178)

Upadhyay R, Boiarsky JA, Pantsulaia G, et al. A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy. Cancer Discov. 2021,11(3):599-613. doi: 10.1158/2159-8290.CD-20-0756

Lotti R, Shu E, Petrachi T, et al. Soluble Fas Ligand Is Essential for Blister Formation in Pemphigus. Front Immunol. 2018,9:370. doi: 10.3389/fimmu.2018.00370

Lakins MA, Ghorani E, Munir H, et al. Cancer-associated fibroblasts induce antigen-specific deletion of CD8 (+) T Cells to protect tumour cells. Nat Commun. 2018,9(1):948. doi: 10.1038/s41467-018-03347-0

Bień K, Żmigrodzka M, Orłowski P, et al. Involvement of Fas/FasL pathway in the murine model of atopic dermatitis. Inflamm Res. 2017,66(8):679-690. doi: 10.1007/s00011-017-1049-z

D'Aloia MM, Caratelli S, Palumbo C, et al. T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G-opsonized target cells. Cytotherapy. 2016,18(2):278-90. doi: 10.1016/j.jcyt.2015.10.014

Linkermann A, Himmerkus N, Rölver L, et al. Renal tubular Fas ligand mediates fratricide in cisplatin-induced acute kidney failure. Kidney Int. 2011,79(2):169-78. doi: 10.1038/ki.2010.317

Kayagaki N, Yamaguchi N, Nagao F, et al. Polymorphism of murine Fas ligand that affects the biological activity. Proc Natl Acad Sci U S A. 1997,94(8):3914-9.